The prevalence of prediabetes in population of Polish men with late-onset hypogonadism

References

• Feldman HA, Longcope C, Derby CA, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts Male Aging Study. J Clin Endocrinol Metab 2002;87:589–98
   PubMed Web of Science ®Google Scholar
• Mazur A, Westerman R, Werdecker A, Mueller U. Testosterone and type 2 diabetes in men. Aging Male 2014;1:18–22
   Google Scholar
• Kim ML, Rolland O, Cepeda JK, et al. Diabetes mellitus in older men. The Aging Male 2006;9:139–47
   PubMed Web of Science ®Google Scholar
• Cho NH, Whiting D, Guariguata L, et al. IDF Diabetes Atlas. 6th ed. International Diabetes Federation; 2013:39–49
   Google Scholar
• Laaksonen DE, Niskanen L, Punnonen K, et al. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 2004;27:1036–41
   PubMed Web of Science ®Google Scholar
• Stellato RK, Feldman HA, Hamdy O, et al. Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts male aging study. Diabetes Care 2000;23:490–4
   PubMed Web of Science ®Google Scholar
• Grossmann M, Thomas MC, Panagiotopoulos S, et al. Low testosterone levels are common and associated with insulin resistance in men with diabetes. J Clin Endocrinol Metab 2008;93:1834–40
   PubMed Web of Science ®Google Scholar
• Allan CA, McLachlan RI. Androgens and obesity. Curr Opin Endocrinol Diabetes Obes 2010;17:224–32
   PubMed Web of Science ®Google Scholar
• Field AE, Colditz GA, Willett WC, et al. The relation of smoking, age, relative weight, and dietary intake to serum adrenal steroids, sex hormones, and sex hormone-binding globulin in middle aged men. J Clin Endocrinol Metab 1994;79:1310–16
   PubMed Web of Science ®Google Scholar
• Tajar A, Huhtaniemi IT, O'Neill TW, et al; EMAS Group. Characteristics of androgen deficiency in late-onset hypogonadism: results from the European Male Aging Study (EMAS). J Clin Endocrinol Metab 2012;5:1508–16
   Google Scholar
• Dhindsa S, Miller MG, McWhirter CL,et al. Testosterone concentrations in diabetic and nondiabetic obese men. Diabetes Care 2010;33:1186–92
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2012;35:1–8
   PubMed Web of Science ®Google Scholar
• Rydén L, Grant PJ, Anker SD, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2013;34:3035–87
   Google Scholar
• Ho CH, Yu HJ, Wang CY, et al. Prediabetes is associated with an increased risk of testosterone deficiency, independent of obesity and metabolic syndrome. PLos One 2013;8:e74173
   PubMed Web of Science ®Google Scholar
• Lunenfeld B, Mskhalaya G, Kalinchenko S, Tischova T. Recommendations on the diagnosis, treatment and monitoring of late-onset hypogonadism in men – a suggested update. Aging Male 2013;4:143–50
   Web of Science ®Google Scholar
• Athyros GV, Ganotakis ES, Mikhailidis DO. The prevalence of the metabolic syndrome using the National Cholesterol Educational Program and International Diabetes Federation definitions. Curr Med Res Opin 2005;21:1157–64
   PubMed Web of Science ®Google Scholar
• Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999;84 3666–72
   PubMed Web of Science ®Google Scholar
• Saukkonen T, Cederberg H, Jokelainen J, et al. Limited overlap between intermediate hyperglycemia as defined by A1C. pp. 5.7–6.4%, impaired fasting glucose, and impaired glucose tolerance. Diabetes Care 2011;34:2314–16
   PubMed Web of Science ®Google Scholar
• Rabijewski M. Papierska L, Zgliczyński W, Piątkiewicz P. The Incidence of hypogonadotropic hypogonadism in type 2 diabetic men in Polish population. BioMed Res Int 2013;2013:767496
   Google Scholar
• Colangelo LA, Ouyang P, Liu K, et al. Association of endogenous sex hormones with diabetes and impaired fasting glucose in men: multi-ethnic study of atherosclerosis. Diabetes Care 2009;32:1049–51
   PubMed Web of Science ®Google Scholar
• Goodman-Gruen D, Barrett-Connor E. Sex differences in the association of endogenous sex hormone levels and glucose tolerance status in older men and women. Diabetes Care 2000;23:912–18
   PubMed Web of Science ®Google Scholar
• Corona G, Rastrelli G, Balercia G, et al. Hormonal association and sexual dysfunction in patients with impaired fasting glucose: a cross-sectional and longitudinal study. J Sex Med 2012;9:1669–80
   PubMed Web of Science ®Google Scholar
• Salving E, Finley M, Zhang L, et al. Androgens and diabetes in men. Results from the Third National Health and Nutrition Examination Survey (NHANES III). Diabetes Care 2007;30:234–8
   PubMedGoogle Scholar
• Piteous N, Dwyer AA, Decius S, et al. The relative role of gonad sex steroids and gonadotropin-releasing hormone pulse frequency in the regulation of follicle-stimulating hormone secretion in men. J Clin Endocrinol Metab 2008;93:2686–92
   PubMed Web of Science ®Google Scholar
• Laughlin GS, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab 2008;93:68–75
   PubMed Web of Science ®Google Scholar
• Muraleedharan V, Marsh H, Kapoor D, et al. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur J Endocrinol 2013;6:725–33
   Google Scholar
• Kapoor D, Aldred H, Clark S, Jones TH. Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: correlations with bioavailable testosterone and visceral adiposity. Diabetes Care 2007;30:911–17
   PubMed Web of Science ®Google Scholar
• Phillips OB, Jing T, Heymsfield SB. Relationships in men of sex hormones, insulin, adiposity, and risk factors for myocardial infarction. Metabolism 2003;52:784–90
   PubMed Web of Science ®Google Scholar
• Jones TH, Arver S, Behre HM, et al. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care 2011;34:828–37
   PubMed Web of Science ®Google Scholar
• Heufelder AE, Saad F, Bunck MC, Gooren L. Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. J Androl 2009;30:726–33
   PubMed Web of Science ®Google Scholar
• Muraleedharan V, Marsh H, Kapoor D, et al. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur J Endocrinol 2013;169:725–33
   PubMed Web of Science ®Google Scholar
• Aversa A, Bruzziches R, Francomano D, et al. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study. J Sex Med 2010;7:3495–503
   PubMed Web of Science ®Google Scholar
• Francomano D, Lenzi A, Aversa A. Effects of five-year treatment with testosterone undecanoate on metabolic and hormonal parameters in ageing men with metabolic syndrome. Int J Endocrinol 2014. (Epub ahead of print)
   Google Scholar
• Haider A, Yassin A, Doros G, Saad F. Effects of long-term testosterone therapy on patients with “diabesity”: results of observational studies of pooled analyses in obese hypogonadal men with type 2 diabetes. Int J Endocrinol 2014. (Epub ahead of print)
   Google Scholar
• Zitzmann M, Faber S, Nieschlag E. Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocrinol Metab 2006;91:4335–43
   PubMed Web of Science ®Google Scholar